Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer
Public ClinicalTrials.gov record NCT05493501. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Three-Arm, Open-Label Phase 3b Clinical Trial of Aumolertinib, Versus Aumolertinib With Chemotherapy, Versus Osimertinib for Patients With Metastatic NSCLC and an EGFR Mutation (TREBLE)
Study identification
- NCT ID
- NCT05493501
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- EQRx International, Inc.
- Industry
- Enrollment
- 8 participants
Conditions and interventions
Conditions
Interventions
- Aumolertinib monotherapy Drug
- Carboplatin Drug
- Cisplatin Drug
- Gemcitabine Drug
- Nab paclitaxel Drug
- Osimertinib monotherapy Drug
- Paclitaxel Drug
- Pemetrexed Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 13, 2022
- Primary completion
- Aug 30, 2023
- Completion
- Aug 30, 2023
- Last update posted
- May 1, 2024
2022 – 2023
United States locations
- U.S. sites
- 8
- U.S. states
- 6
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Highlands Oncology Group | Springdale | Arkansas | 72762 | — |
| Memorial Cancer Institute | Hollywood | Florida | 33021 | — |
| Memorial Cancer Institute | Pembroke Pines | Florida | 33028 | — |
| QCCA - Mission Blood & Cancer | Des Moines | Iowa | 50314 | — |
| Summit Health | Florham Park | New Jersey | 07932 | — |
| SCRI - Tennessee Oncology PLLC- Chattanooga | Chattanooga | Tennessee | 37404 | — |
| SCRI - Tennessee Oncology- Nashville | Nashville | Tennessee | 37203 | — |
| Northwest Medical Specialties, PLLC | Tacoma | Washington | 98405 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05493501, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 1, 2024 · Synced May 10, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05493501 live on ClinicalTrials.gov.